AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 281 min read$RLAY

SVF Pauling (Cayman) Ltd sold $116.4M of RLAY (indirect holdings)

SVF Pauling (Cayman) Ltd sold 6,000,000 indirectly-held shares of Relay Therapeutics, Inc. (RLAY) at $19.40 ($116.40M total) on 2026-08-25. Filed jointly with SOFTBANK VISION FUND (AIV M2) L.P. (10% owner) and SB INVESTMENT ADVISERS (UK) LTD (10% owner).

Original reporting
SEC EDGAR · SVF Pauling (Cayman) Ltd, SOFTBANK VISION FUND (AIV M2) L.P., SB INVESTMENT ADVISERS (UK) LTD
Published Aug 28, 2026, 1:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RLAY
Bearish
high confidence
Mentioned
$RLAY
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYBearishMed
01

Why it matters

Large insider sell could trigger short covering or price decline; investors may reassess valuation.

02

Market read

First-report insider sale of $116M may influence RLAY trading activity.

03

What to watch

Sale executed via indirect holdings; tax or portfolio rebalancing could be motive.

Relevance 8/10Novelty 8/10Timing: post-market 2026-08-25

Background

SEC Form 4 filing discloses insider transaction for Relay Therapeutics.

Company-level read

Ticker impact

$RLAYBearishHigh confidence
Context

Form 4 shows SVF Pauling (Cayman) Ltd sold 6,000,000 shares of Relay Therapeutics at $19.40, reducing its indirect stake.

Expected impact

Potential short-term downside as market absorbs $116M sale.

Evidence & confidence

Sale size exceeds $100M and represents a 10% owner reducing holdings; market typically reacts negatively to sizable insider disposals.

Market effects

Sector

May weigh on biotech sector sentiment as insider sell suggests valuation concerns.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minor global impact; primarily relevant to RLAY shareholders.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Company
    Relay Therapeutics, Inc.

    Biotech firm developing therapeutic programs.

  • Insider Entity
    SVF Pauling (Cayman) Ltd

    10% owner of Relay Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLAY insider trading history →

Related articles

AUG 6
$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay

SEC EDGAR 8-K6 min
JUN 2
$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.

rttnews.com1 min